Dexamethasone acetate is under clinical development by Oculis and currently in Phase III for Ocular Inflammation. According to GlobalData, Phase III drugs for Ocular Inflammation have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Dexamethasone acetate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Dexamethasone acetate overview
Dexamethasone acetate (DexNP, OC-118, OCS-01) is under development for the treatment of macular edema, diabetic macular edema and post cataract operation inflammation and pain. The tehrapeutic candidate is formulated as eye drop suspension and administered through ophthalmic route of administration. It is a nanoparticle composed of gamma-cyclodextrin dexamethasone complex. Dexamethasone is synthetic glucocorticoids which target glucocorticoid receptors. The drug candidate is a complex of drug and cyclodextrin nanoparticle developed based on solubilizing nano-particle (SNP) drug-delivery technology and OPTIREACH. It was also under development of posterior and intermediate uveitis, glaucoma and ocular inflammation after surgery.
For a complete picture of Dexamethasone acetate’s drug-specific PTSR and LoA scores, buy the report here.